FBRX

Forte Biosciences Inc

FBRX, USA

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

https://www.fortebiorx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FBRX
stock
FBRX

Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX Defense World

Read more →
FBRX
stock
FBRX

Stock Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$52.25

Analyst Picks

Strong Buy

4

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.85

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-21.03 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-18.21 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.15

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 116.72% of the total shares of Forte Biosciences Inc

1.

Fred Alger Management, LLC

(13.0191%)

since

2025/06/30

2.

HHG PLC

(11.2191%)

since

2025/06/30

3.

Orbimed Advisors, LLC

(9.6274%)

since

2025/06/30

4.

Federated Hermes Inc

(8.6242%)

since

2025/06/30

5.

Tybourne Capital Management (HK) Ltd

(6.3272%)

since

2025/06/30

6.

Federated Hermes Kaufmann R

(5.0528%)

since

2025/06/30

7.

Federated Hermes Kaufmann Growth

(5.0528%)

since

2025/06/30

8.

Bvf Inc

(4.7322%)

since

2025/06/30

9.

Cable Car Capital LLC

(4.0216%)

since

2025/06/30

10.

Sphera Funds Management Ltd.

(3.9823%)

since

2025/06/30

11.

Vanguard Group Inc

(3.9164%)

since

2025/06/30

12.

Ikarian Capital, LLC

(3.8321%)

since

2025/06/30

13.

Alger Small Cap Focus Composite

(3.7273%)

since

2025/06/30

14.

Alger Small Cap Focus I

(3.7273%)

since

2025/06/30

15.

Federated Hermes Kaufmann Small Cap A

(3.4304%)

since

2025/06/30

16.

Federated Hermes Kaufmann Small Cap Grow

(3.4304%)

since

2025/06/30

17.

Vanguard Total Stock Mkt Idx Inv

(2.9911%)

since

2025/07/31

18.

Adage Capital Partners Gp LLC

(2.6811%)

since

2025/06/30

19.

Woodline Partners LP

(2.6702%)

since

2025/06/30

20.

Alger LIfe Sciences Innovation Composite

(1.3404%)

since

2025/06/30

21.

Alger Large Cap Growth Composite

(1.271%)

since

2025/06/30

22.

Alger Large Cap Growth I-2

(1.271%)

since

2025/06/30

23.

Alger Small Cap Growth B

(1.2689%)

since

2025/06/30

24.

Heights Capital Management Inc

(1.1504%)

since

2025/06/30

25.

Alger Health Sciences A

(1.0824%)

since

2025/06/30

26.

Alger Small Cap Growth I-2

(0.8277%)

since

2025/06/30

27.

Biotech Growth Ord

(0.7157%)

since

2025/05/31

28.

Millennium Management LLC

(0.58%)

since

2025/06/30

29.

Alger Dynamic Opportunities A

(0.5773%)

since

2025/06/30

30.

Perceptive Advisors LLC

(0.5485%)

since

2025/06/30

31.

Geode Capital Management, LLC

(0.5156%)

since

2025/06/30

32.

Vanguard Institutional Extnd Mkt Idx Tr

(0.513%)

since

2025/07/31

33.

Alger Small Cap Growth Institutional I

(0.4756%)

since

2025/06/30

34.

Alger Small Cap Growth Composite

(0.4756%)

since

2025/06/30

35.

BOOTHBAY FUND MANAGEMENT, LLC

(0.4716%)

since

2025/06/30

36.

Alger Mid Cap 40 Composite

(0.459%)

since

2025/06/30

37.

Alger 35 ETF

(0.3801%)

since

2025/08/29

38.

Mink Brook Asset Management LLC

(0.3128%)

since

2025/06/30

39.

BlackRock Inc

(0.271%)

since

2025/06/30

40.

Envestnet Asset Management Inc

(0.1517%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.99

EPS Estimate

-0.08

EPS Difference

-0.91

Surprise Percent

-1137.5%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.